Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

RZL-012 for Dercum's Disease Lipomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04229030
Recruitment Status : Not yet recruiting
First Posted : January 14, 2020
Last Update Posted : January 14, 2020
Sponsor:
Information provided by (Responsible Party):
Raziel Therapeutics Ltd.

Brief Summary:
Thirty-eight (38) subjects will be included in the study. Subjects will be randomized in a ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be enrolled in 3 clinical sites.

Condition or disease Intervention/treatment Phase
Dercum's Disease Lipomas Drug: RZL-012 Drug: Vehicle Phase 2

Detailed Description:

This is a multi-center, randomized, double blind, placebo controlled clinical trial in DD subjects having lipomas. Subjects will be randomized, in a 1:1 ratio, into two groups injected with either RZL-012 or vehicle.

Once the study ends and codes are opened, 84 days after dosing, placebo-treated subjects will be offered the option of receiving treatment with RZL-012 and followed up for an additional 84 days.

At least 4 lipomas/nodules, preferably 6, and no more than 8, will be injected per subject, two of which will be medium (4-5.9 cm), large (6-7.9 cm) or extra-large (8-10 cm) in diameter. Dosing will be according to lipoma size, where the total injected dose will not exceed 240 mg per patient (48 injections at 5mg/injection).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2B Clinical Trial for the Evaluation of Efficacy and Safety of RZL-012 in Subjects Having Dercum's Disease Lipomas
Estimated Study Start Date : May 1, 2020
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : March 30, 2021


Arm Intervention/treatment
Active Comparator: RZL-012

A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL RZL-012 (5mg).

Lipomas in the size of:

2-3.9 cm will be dozed with 0.4mL RZL-012 (20mg). 4-5.9 cm will be dozed with 0.8mL RZL-012 (80mg). 6-7.9 cm will be dozed with 1 mL RZL-012 (100mg). 8-10 cm will be dozed with 1.2 mL RZL-012 (120mg).

Drug: RZL-012
small synthetic molecule for the treatment of Dercum's Disease lipomas

Placebo Comparator: Vehicle of RZL-012

A single-treatment injection, multiple subcutaneous injections of vehicle administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL vehicle.

Lipomas in the size of:

2-3.9 cm will be dozed with 0.4mL vehicle. 4-5.9 cm will be dozed with 0.8mL vehicle. 6-7.9 cm will be dozed with 1 mL vehicle. 8-10 cm will be dozed with 1.2 mL vehicle.

Drug: Vehicle
Vehicle of RZL-012 drug product
Other Name: placebo




Primary Outcome Measures :
  1. Efficacy - Change in lipomas dimensions [ Time Frame: 0-84 days ]
    Evaluation of the efficacy of RZL-012 following injection into lipomas/nodules of Dercum's Disease (DD) subjects. Efficacy will be determined by ultrasound assessment of the lipoma/nodule dimensions after treatment vs baseline. Lipomas Dimensions will be measured for active vs. placebo at days 28,56,84


Secondary Outcome Measures :
  1. Key secondary outcome - efficacy - Improvement in pain assessment of individual lipomas [ Time Frame: 0-84 days ]
    Assessment of lipoma/nodule associated pain using the Comparative Pain Scale. 0 is "no pain" and 10 is "worst pain". Pain measured for active vs. placebo at days 28,56,84

  2. Safety change from baseline in clinical laboratory tests [ Time Frame: 0-28 days ]
    Safety will be assessed by by change-from-baseline values for clinical laboratory tests. measured for active vs. placebo at days 1 and 28 following injection. Number of subjects with abnormal laboratory values will be compared in both study arms.


Other Outcome Measures:
  1. Exploratory [ Time Frame: 0-84 Days ]
    Improvement in Quality of Life - QOL questionnaire. Improvement will be measured for active vs. placebo at Day 0 and Day 84 following treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 4 painful lipomas of appropriate size to be injected on a background of Dercum's Disease.
  • Generally considered healthy according to medical history, physical examination, electrocardiogram (ECG) and laboratory evaluation with an emphasis on metabolic parameters (fasting glucose concentration < 200 mg/dL).
  • Subjects must be able to adhere to the visit schedule and protocol requirements and be capable of completing the study.
  • Males or females in the age of fertility are willing to refrain from sexual activity or agree to use a double-barrier contraceptive device (e.g., condom and spermicide) for 4 weeks after treatment with RZL 012.
  • Subjects must sign an informed consent indicating they are aware of the investigational nature of the study.

Exclusion Criteria:

  • Unable to tolerate subcutaneous injections.
  • Pregnant women.
  • Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders, that in the opinion of the investigator places the subject at significant risk.
  • Positive blood screen for Hepatitis B surface antigen (HbSAg), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV).
  • Subjects with a clinical history of active primary or secondary immunodeficiency, autoimmune disease or subjects taking immunosuppressive drugs such as corticosteroids
  • Subjects with dysfunctional gallbladder activity, e.g. underwent cholecystectomy or cholecystitis.
  • As a result of medical review and physical examination, the PI (or medically qualified nominee) considers the subject unfit for the study.
  • Known sensitivity to components of the injection formulation.
  • Prior wound, tattoo or infection in the treated area.
  • Prior invasive treatment such as surgery or injectable drug at the RZL-012 injected area.
  • Subjects treated chronically at least 3 months prior to study entry with systemic steroids or immunosuppressive drugs.
  • Subjects treated chronically at least one week prior to study entry with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
  • Current participation or participation within 3 months prior to the start of this study in a drug or other investigational research study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04229030


Contacts
Layout table for location contacts
Contact: Racheli Gueta, PhD 972-8-9126941 racheli@raziel-therapy.com

Sponsors and Collaborators
Raziel Therapeutics Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Karen Herbst, MD Arizona
Layout table for additonal information
Responsible Party: Raziel Therapeutics Ltd.
ClinicalTrials.gov Identifier: NCT04229030    
Other Study ID Numbers: RZL-012-DD-P2bUS-001
First Posted: January 14, 2020    Key Record Dates
Last Update Posted: January 14, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipoma
Adiposis Dolorosa
Neoplasms, Adipose Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Lipomatosis
Skin Diseases
Lipid Metabolism Disorders
Metabolic Diseases